Indegene Ltd

Indegene Earnings Call Transcript: Key Takeaways

Strong top-line growth driven by pharma digital transformation, but near-term margins are compressed by annual wage hikes and mutual fund mark-downs.

Indegene Management Change

Indegene's Company Secretary and Compliance Officer Srishti Ramesh Kaushik resigned, effective 02-Dec-2026. The resignation cites future career advancement.

Indegene Employee Stock Options

Indegene Limited allotted 52,194 equity shares under its ESOP schemes, raising paid-up capital to Rs.48.21 Crore. No cash fund raise is involved, so no event value applies.

Indegene Investor Presentation: Key Takeaways

Q2 FY27 revenue INR 11,223M (+39.5% YoY, +5.6% QoQ), EBITDA margin 16.7%, PAT INR 1,123M (+10% YoY). BioPharm integration ahead of plan.

Indegene Results Update

Indegene reported Q2 FY27 revenue of ₹11,223M, up 39.5% YoY, with PAT of ₹1,123M. H1 USD revenue growth reached a four-year high of 27.0%.

Indegene Q2 FY27 Results: Net Profit ₹112.3 Cr, Up 10.0% YoY

Indegene Ltd reported revenue from operations of ₹1,122 Cr (+39.6% YoY) and net profit of ₹112.3 Cr (+10.0% YoY) for Q2 FY27.

Key figure

Net profit ₹112.3 Cr · +10.0% YoY

Indegene Merger & Restructuring

Indegene Ltd disclosed that its step-down wholly owned subsidiary, Indegene Portugal Unipessoal LDA, was incorporated on 23 October 2026. The entity has nil turnover and is yet to begin operations.

Indegene Business Update

Indegene received Frost & Sullivan's 2026 Global Enabling Technology Leadership award for AI-powered pharma commercialization. The recognition highlights its domain-led AI platform and workflow transformation capabilities.

Indegene Other Announcement

Indegene Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing details share distribution across promoter and public shareholder categories.

Indegene Management Change

Indegene's Non-Executive Director Mr. Mark Dzialga resigned effective October 29, 2026, following Brighton Park Capital's sale of its entire stake. No other material board changes are disclosed.

Indegene Employee Stock Options

Indegene Limited has allotted 16,110 equity shares under its ESOP Scheme 2020. The board also approved an amendment to the company's POSH policy.

Indegene Business Update

Indegene held its 2026 Digital Summit in Philadelphia, drawing 120+ pharma leaders and 19 speakers. The event showcased the company's AI-native pharma enablement capabilities.

Indegene Board Meeting Date

Indegene Limited scheduled a board meeting for October 29, 2026, to approve unaudited financial results and consider share allotments under ESOP and RSU schemes.

Indegene Business Update

Indegene Limited hosted its Indegene Digital Summit 2026, focusing on operationalizing AI within life sciences. The event also featured the presentation of the VITAL Awards 2026.

Indegene Merger & Restructuring

Indegene Limited completed the internal merger of its two indirect wholly owned subsidiaries in Germany. This reorganization does not impact Indegene's financial position or operations.

Indegene Legal & Regulatory

Indegene Limited received preliminary court approval for a class action settlement related to the U.S. Telephone Consumer Protection Act. Final hearing is scheduled for January 2027.

Indegene Legal & Regulatory

The U.S. Court preliminarily approved the class action settlement for Indegene's subsidiary. The maximum settlement fund is approximately ₹44.84 Crore.

Value

₹44.84 Cr

Indegene Legal & Regulatory

Indegene Limited's subsidiary, Indegene Inc., finalized a class-action settlement framework regarding U.S. fax communication violations. The maximum potential settlement fund is USD 4.72 million (₹44.84 Crore).

Value

₹44.84 Cr

Indegene Legal & Regulatory

Indegene Limited's subsidiary finalized a USD 4.72 million class-action settlement agreement regarding U.S. TCPA violations. The settlement, involving approximately 18,851 unique fax numbers, remains subject to court approval.

Value

₹45.24 Cr

Indegene Management Change

Indegene Limited shareholders approved the appointment of Ms. Jill Mary De Simone as an Independent Director for a three-year term starting January 22, 2026.

Execution

3 years

Indegene Annual General Meeting

Indegene Ltd held its 28th Annual General Meeting on August 13, 2026. The meeting transacted business including dividend declaration and appointment of directors.

Indegene Capital Structure Change

BPC Genesis Fund I SPV Limited, a non-promoter entity, sold its entire 5.757% stake in Indegene Limited. The open market transaction involved 13,862,223 equity shares.

Indegene Earnings Call Transcript: Key Takeaways

Indegene delivered its strongest Q1 growth in four years, yet remains burdened by elevated costs from strategic investments and workforce transformation.

Indegene Employee Stock Options

Indegene Limited allotted 12,451 equity shares under its ESOP scheme. This allotment marginally increases the company's paid-up share capital.

Indegene Investor Presentation: Key Takeaways

Indegene reported Q1'FY27 revenue of ₹10,631M (+39.7% YoY) with an EBITDA margin of 16.9%. The strategy focuses on scaling GenAI-powered solutions and deepening engagement with large pharma.

Indegene Results Update

Indegene reported strong Q1 FY27 results with revenue of ₹1,063.1 Crore, up 39.7% YoY. EBITDA rose to ₹179.5 Crore with a 16.9% margin.

Value

₹1,063 Cr

Indegene Other Announcement

Indegene Limited filed its Monitoring Agency Report for the quarter ended June 30, 2026, regarding the utilization of its IPO proceeds.

Indegene Q1 FY27 Results: Net Profit ₹116.2 Cr, Down 0.2% YoY

Indegene Ltd reported revenue from operations of ₹1,063 Cr (+39.7% YoY) and net profit of ₹116.2 Cr (-0.2% YoY) for Q1 FY27.

Key figure

Net profit ₹116.2 Cr · -0.2% YoY

Indegene Annual General Meeting

Indegene Limited scheduled its 28th AGM for August 13, 2026. Key agenda items include declaring a Rs 2.25 per share dividend and director appointments.

Indegene Business Update

Indegene Limited submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report details the company's ESG performance and adherence to NGRBC principles.